David E. Schulman advises life sciences companies, financial institutions, private equity fund sponsors, and venture capital firms in both the United States and Europe on corporate and securities matters.
Mr. Schulman has extensive experience representing public and private companies, particularly in the life sciences and investment management sectors, in connection with acquisitions, divestitures, and other significant corporate transactions, including tender offers, stock-for-stock mergers, proxy contests, cash mergers, spin-offs, restructurings, stock and asset acquisitions and dispositions, and troubled company M&A and bankruptcy-related transactions.
He also frequently advises life sciences and other technology-based companies on domestic and cross-border collaborations, co-promotions, licenses, and distribution arrangements. Mr. Schulman is ranked among the top lawyers for life sciences in the United States by the 2017 edition of leading legal directory Chambers USA, which describes him as “very impressive.”
Mr. Schulman has also been listed as a leading lawyer for life sciences by Chambers Global, where he was praised for being “one of the best business and corporate lawyers in the life sciences sector” with “a deep knowledge of the industry, which he successfully combines with great legal skills.”
In addition, Mr. Schulman has been recognized for his work in healthcare: life sciences and for mergers and acquisitions by legal directory The Legal 500 (U.S.), where he is cited for his “ability to mediate in difficult commercial negotiations between the parties.”
He is also listed as a “Life Sciences Star” in LMG Life Sciences, and has been recommended for life sciences: commercial and partnering matters in the United States by Practical Law Company.
Mr. Schulman was based in Dechert’s London office for seven years and currently divides his time between the firm’s London and Washington, D.C. offices. He is also a former co-head of the firm’s Life Sciences practice.
- The University of Edinburgh, General Course Study, 1981
- University of Pennsylvania, B.A., 1982
- University of Pennsylvania Law School, J.D., 1985
- District of Columbia
- Supreme Court of Pennsylvania
- 2016 collaboration and acquisition option with Anokion SA for the development of novel tolerance-inducing therapeutics for autoimmune diseases. Under the terms of the collaboration agreement, Anokion received a US$45 million upfront payment.and Celgene obtained an equity interest in Anokion and the exclusive right to acquire Anokion at pre-specified option exercise points.
- 2016 collaboration with Agios Pharmaceuticals, Inc. focused on metabolic immuno-oncology. Under the terms of the collaboration, Agios received an upfront cash payment of US$200 million plus the potential for additional payments if certain development and regulatory milestones are achieved.
- 2015 collaboration with Nurix, Inc. for the discovery and development of small-molecule treatments that target the body’s ubiquitin proteasome system. Under the terms of the collaboration, Nurix received US$150 million up front plus an undisclosed equity investment.
- 2015 acquisition of Quanticel Pharmaceuticals, Inc., a privately held biotechnology company focused on cancer drug discovery for US$100 million at closing and an additional earnout of US$385 million.
- 2013 collaboration with Forma Therapeutics Holdings, LLC with research and early development milestones of US$200 million.
- Valneva on numerous acquisition and licensing matters, including its 2015 acquisition of the Scandinavian-based Dukoral business from Johnson & Johnson.
- FMC Corporation (NYSE:FMC) in its acquisition of Phytone Ltd., a natural colors producer based in the United Kingdom.
- Nuvo Research Inc. (TSX: NRI) and its wholly owned subsidiary ZARS Pharma, Inc. in licensing exclusive rights to Galen US Incorporated to market and sell Nuvo’s Synera patch throughout the United States for its current indication.
Rate : $$$